Previous studies have demonstrated inactivation of the Met pathway by specific small inhibitors [42], [43], which are particularly effective in the treatment of ‘Met oncogene-addicted’ carcinomas [40], and we suggest that OCC is another optimal target for Met-targeting therapies. The gene discussed is MET; the disease is carcinoma.